4//SEC Filing
GOLDSMITH MARK A 4
Accession 0001610717-25-000403
CIK 0001628171other
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 4:15 PM ET
Size
12.7 KB
Accession
0001610717-25-000403
Insider Transaction Report
Form 4
GOLDSMITH MARK A
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-25$4.09/sh+60,000$245,400→ 307,863 total - Sale
Common Stock
2025-11-25$75.08/sh−60,000$4,504,962→ 247,863 total - Sale
Common Stock
2025-11-25$75.00/sh−3,000$225,000→ 67,424 total(indirect: By Trust) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−60,000→ 77,708 totalExercise: $4.09From: 2023-03-13Exp: 2029-03-12→ Common Stock (60,000 underlying)
Holdings
- 570,050(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
- [F2]Includes 193,475 restricted stock units.
- [F3]This transaction was executed in multiple trades at prices ranging from $75.00 to $75.3650. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Held by Jonathan Goldsmith Revocable Trust.
- [F5]Held by Rebecca Goldsmith Revocable Trust.
- [F6]Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001246842
Filing Metadata
- Form type
- 4
- Filed
- Nov 25, 7:00 PM ET
- Accepted
- Nov 26, 4:15 PM ET
- Size
- 12.7 KB